Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease

被引:572
作者
Smith, Gordon, I [1 ]
Shankaran, Mahalakshmi [2 ]
Yoshino, Mihoko [1 ]
Schweitzer, George G. [1 ]
Chondronikola, Maria [1 ]
Beals, Joseph W. [1 ]
Okunade, Adewole L. [1 ]
Patterson, Bruce W. [1 ]
Nyangau, Edna [2 ]
Field, Tyler [2 ]
Sirlin, Claude B. [3 ]
Talukdar, Saswata [4 ]
Hellerstein, Marc K. [2 ]
Klein, Samuel [1 ]
机构
[1] Washington Univ, Sch Med, John T Milliken Dept Med, Atkins Ctr Excellence Obes Med,Ctr Human Nutr, St Louis, MO 63110 USA
[2] Univ Calif Berkeley, Coll Nat Resources, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA
[3] Univ Calif San Diego, Liver Imaging Grp, La Jolla, CA 92093 USA
[4] Merck & Co Inc, San Francisco, CA USA
关键词
ADIPOSE-TISSUE; TRANSCRIPTION FACTOR; NONDIABETIC PATIENTS; VISCERAL FAT; METABOLISM; SREBP-1C; HUMANS; STEATOSIS; PLASMA; ACIDS;
D O I
10.1172/JCI134165
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BACKGROUND. An increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear. METHODS. Hepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%. RESULTS. The contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations. CONCLUSIONS. These data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.
引用
收藏
页码:1453 / 1460
页数:8
相关论文
共 63 条
[1]   Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia [J].
Adiels, M ;
Borén, J ;
Caslake, MJ ;
Stewart, P ;
Soro, A ;
Westerbacka, J ;
Wennberg, B ;
Olofsson, SO ;
Packard, C ;
Taskinen, MR .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (08) :1697-1703
[2]   THE USE OF AREAS UNDER CURVES IN DIABETES RESEARCH [J].
ALLISON, DB ;
PAULTRE, F ;
MAGGIO, C ;
MEZZITIS, N ;
PISUNYER, FX .
DIABETES CARE, 1995, 18 (02) :245-250
[3]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[4]   The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans [J].
Benhamed, Fadila ;
Denechaud, Pierre-Damien ;
Lemoine, Maud ;
Robichon, Celine ;
Moldes, Marthe ;
Bertrand-Michel, Justine ;
Ratziu, Vlad ;
Serfaty, Lawrence ;
Housset, Chantal ;
Capeau, Jacqueline ;
Girard, Jean ;
Guillou, Herve ;
Postic, Catherine .
JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (06) :2176-2194
[5]   Selective versus total insulin resistance: A pathogenic paradox [J].
Brown, Michael S. ;
Goldstein, Joseph L. .
CELL METABOLISM, 2008, 7 (02) :95-96
[6]   Molecular mediators of hepatic steatosis and liver injury [J].
Browning, JD ;
Horton, JD .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (02) :147-152
[7]   Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms [J].
Bugianesi, E ;
Gastaldelli, A ;
Vanni, E ;
Gambino, R ;
Cassader, M ;
Baldi, S ;
Ponti, V ;
Pagano, G ;
Ferrannini, E ;
Rizzetto, M .
DIABETOLOGIA, 2005, 48 (04) :634-642
[8]   Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5 [J].
Buse, John B. ;
Rodbard, Helena W. ;
Serrano, Carlos Trescoli ;
Luo, Junxiang ;
Ivanyi, Tibor ;
Bue-Valleskey, Juliana ;
Hartman, Mark L. ;
Carey, Michelle A. ;
Chang, Annette M. .
DIABETES CARE, 2016, 39 (01) :92-100
[9]   Hepatic cytochrome p450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis [J].
Chalasani, N ;
Gorski, JC ;
Asghar, MS ;
Asghar, A ;
Foresman, B ;
Hall, SD ;
Crabb, DW .
HEPATOLOGY, 2003, 37 (03) :544-550
[10]   Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance [J].
Choi, Cheol Soo ;
Savage, David B. ;
Kulkarni, Ameya ;
Yu, Xing Xian ;
Liu, Zhen-Xiang ;
Morino, Katsutaro ;
Kim, Sheene ;
Distefano, Alberto ;
Samuel, Varman T. ;
Neschen, Susanne ;
Zhang, Dongyan ;
Wang, Amy ;
Zhang, Xian-Man ;
Kahn, Mario ;
Cline, Gary W. ;
Pandey, Sanjay K. ;
Geisler, John G. ;
Bhanot, Sanjay ;
Monia, Brett P. ;
Shulman, Gerald I. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (31) :22678-22688